Point of Care & Rapid Diagnostics Market by Product (Glucose, Infectious Disease(HIV, Hepatitis C), Pregnancy Test), Platform (Microfluidics, Dipsticks), Mode of Purchase (OTC, Prescription), End User (Pharmacy, Hospital, Home) - Global Forecast to 2027

ポイントオブケア(POC)&迅速診断の世界市場予測(~2027):製品別、プラットフォーム別、購入方法別、エンドユーザー別

◆タイトル:Point of Care & Rapid Diagnostics Market by Product (Glucose, Infectious Disease(HIV, Hepatitis C), Pregnancy Test), Platform (Microfluidics, Dipsticks), Mode of Purchase (OTC, Prescription), End User (Pharmacy, Hospital, Home) - Global Forecast to 2027
◆商品コード:MD2702-22
◆調査・発行会社:MarketsandMarkets
◆発行日:2022年3月8日
◆ページ数:359
◆レポート形式:PDF / 英語
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆産業分野:医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧)USD4,950 ⇒換算¥633,600見積依頼/購入/質問フォーム
Multi User (Five User)USD6,650 ⇒換算¥851,200見積依頼/購入/質問フォーム
Corporate License (全社内共有可)USD8,150 ⇒換算¥1,043,200見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、レポートに記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はMarketsandMarketsの日本における正規販売代理店です。

【レポートの概要】

マーケッツアンドマーケッツ社は、世界のポイントオブケア(POC)&迅速診断市場規模が、2022年432億ドルから2027年720億ドルまで年平均10.8%成長すると予測しています。本調査レポートは、ポイントオブケア(POC)&迅速診断の世界市場について調査し、イントロダクション、調査手法、エグゼクティブサマリー、プレミアムインサイト、市場概要、製品別(ぶどう糖モニタリング製品、新型コロナウイルス感染症検査製品、心血管代謝モニタリング製品、感染症検査製品、凝固監視製品)分析、プラットフォーム別(ラテラルフローアッセイ、イムノ分析、マイクロ流体、ディップスティック、分子診断)分析、購入方法別(OTC、処方箋)分析、エンドユーザー別(臨床研究室、外来治療施設、薬局・小売、病院・救急センター、家庭)分析、地域別分析、競争状況、企業情報など、以下の構成でまとめております。
・イントロダクション
・調査手法
・エグゼクティブサマリー
・プレミアムインサイト
・市場概要
・世界のポイントオブケア(POC)&迅速診断市場規模:製品別(ぶどう糖モニタリング製品、新型コロナウイルス感染症検査製品、心血管代謝モニタリング製品、感染症検査製品、凝固監視製品)
・世界のポイントオブケア(POC)&迅速診断市場規模:プラットフォーム別(ラテラルフローアッセイ、イムノ分析、マイクロ流体、ディップスティック、分子診断)
・世界のポイントオブケア(POC)&迅速診断市場規模:購入方法別(OTC、処方箋)
・世界のポイントオブケア(POC)&迅速診断市場規模:エンドユーザー別(臨床研究室、外来治療施設、薬局・小売、病院・救急センター、家庭)
・世界のポイントオブケア(POC)&迅速診断市場規模:地域別
・競争状況
・企業情報

“The global point of care diagnostics market is expected to reach USD 72.0 billion by 2027 from an estimated USD 43.2 billion in 2022, at a CAGR of 10.8% from 2022 to 2027.”
Point-of-care testing (POCT) includes screening or diagnostic tests performed outside traditional laboratories. These tests are designed to be used at or near the site where the patient is located (such as at home, in an ambulance, at a physician’s office, and other locations). POCT allows rapid and reliable diagnostic testing through which outcomes can be obtained instantly, helping physicians/patients to make decisions related to care remotely and as soon as possible. Market growth is mainly driven by the high prevalence of infectious diseases, supportive government policies and rising number of CLIA-waived POC tests. In addition, healthcare decentralization and greater investments and funding for product development are expected to offer growth opportunities for players in the point of care diagnostics market. POC tests can greatly improve the management of infectious diseases, especially in developing countries where access to timely medical care is a challenge and the healthcare infrastructure is antiquated and sparse. According to UNAIDS, around 20.6 million people were living with HIV in East and Southern Africa in 2018. In 2019, 20,000 new HIV cases were registered in the Middle East and North Africa (Source: UNAIDS Data 2020). In the Asia Pacific, an estimated 5.8 million people were suffering from HIV in 2019, led by India and China. According to UNAIDS, in 2019, approximately 2.1 million people in India were infected with HIV. The high prevalence of HIV is likely to boost the demand for point-of-care diagnostics, further accelerating the treatment of HIV infection.

Listed below are important statistics related to major infectious diseases in developing countries:
According to the WHO, India has the highest tuberculosis burden, with an estimated incidence of 2.64 million cases in 2020.
• In 2019, around 4.3 million new tuberculosis cases were reported in Southeast Asia, and 632,000 people died due to TB infections in this region (Source: WHO).
• According to the National Influenza Policy 2017, around 10,000 deaths and 40,000 hospitalizations are caused due to influenza in South Africa each year.
• According to the WHO, 1.2 million people in Southeast Asia suffer from malaria, with India alone accounting for ~76% of the total malaria cases.
• During 2014–2016, West Africa reported the largest Ebola epidemic in the region; in two and a half years, the outbreak resulted in more than 28,600 cases and 11,325 deaths.
• In 2020, an estimated 15,898 people in Brazil were at risk of Zika virus infections, down from over 30,000 cases reported a year earlier.

The high prevalence of infectious diseases, coupled with the inadequate healthcare infrastructural facilities in developing countries, is expected to drive the adoption of POC testing.

“The Glucose Monitoring Products segment accounted for the largest share of the point of care diagnostics market, by product type, in 2021”
Based on products, the point-of-care diagnostics market is segmented into glucose monitoring products, cardiometabolic monitoring products, COVID-19 testing products, infectious disease testing products, coagulation monitoring products, pregnancy & fertility testing products, hematology testing products, tumor/cancer marker testing products, fecal occult testing products, urinalysis testing products, drug-of-abuse testing products, cholesterol testing products, and other products. In 2021, the glucose monitoring products segment accounted for the largest share of the point-of-care diagnostics market. This can be attributed to the growing diabetic patient population base, ongoing technological advancements, and the growing preference for home glucose testing.

“The Lateral Flow Assays segment accounted for the largest share of the point of care diagnostics market, by platform, in 2021”
Based on platform, the point-of-care diagnostics market is segmented into lateral flow assays, immunoassays, microfluidics, dipsticks, and molecular diagnostics. The lateral flow assays segment accounted for the largest share of the market in 2021. The widespread adoption of lateral flow assays in POC testing as a replacement for lengthy, conventional laboratory procedures is a key factor contributing to the growth of this segment.

“The OTC Testing Products segment, by mode of purchase, accounted for the largest share of the global point of care diagnostics market in 2021”
On the basis of mode of purchase, the point-of-care diagnostics market is segmented into OTC testing products and prescription-based testing products. The OTC testing products segment accounted for the largest share of the market in 2021. The growing prevalence of lifestyle diseases and the favorable reimbursement scenario for OTC testing products are the major factors driving the growth of this market segment.

“On the basis of End Users, Hospitals & Critical Care Centers segment accounted for the largest share of the global point of care diagnostics market, in 2021”
On the basis of end users, the point-of-care diagnostics market is segmented into clinical laboratories; ambulatory care facilities and physicians’ offices; pharmacies, retail clinics, and E-commerce platforms; hospitals, critical care centers, and urgent care centers; home care & self-testing; and other end users. The hospitals & critical care centers segment is expected to dominate the market during the forecast period, owing to the increasing adoption of POC devices offering reduced turnaround time. The clinical laboratories segment accounted for the largest share of the point-of-care diagnostics market in 2021. However, the home care and self-testing segment is projected to register the highest CAGR during the forecast period, owing to the increasing prevalence of chronic diseases (requiring long-term care and frequent monitoring), growing awareness about home care, and the increasing availability of user-friendly and advanced POC diagnostic products.

“The Latin America market is expected to grow at the highest CAGR during the forecast period”
The global point of care diagnostics market is segmented into North America (comprising the US and Canada), Europe (includes Germany, France, and the UK), the Asia Pacific (includes Japan, China, India), Latin America (Brazil, Mexico), and the Middle East & Africa. In 2021, North America accounted for the largest share of this market, followed by Europe. The rising prevalence of lifestyle diseases, growing number of product approvals, and government initiatives to support the wider adoption of POC testing products are the key factors driving the growth of the North American point-of-care diagnostics market. On the other hand, the Latin American market is projected to register the highest growth during the forecast period due to government efforts to increase awareness about the early detection of diseases and regular health check-ups, further promoting point-of-care devices.

A breakdown of the primary participants referred to for this report is provided below:
• By Company Type: Tier 1–48%, Tier 2–36%, and Tier 3– 16%
• By Designation: C-level–10%, Director-level–14%, and Others–76%
• By Region: North America–40%, Europe–32%, Asia Pacific–20%, Latin America–5%, and the Middle East & Africa–3%

As of 2020, the point of care diagnostics market is dominated by Roche Diagnostics (Switzerland), Abbott Laboratories (US), Siemens Healthineers (Germany), Danaher Corporation (US), Quidel Corporation (US). Other leading players are Becton, Dickinson, and Company (US), Biomeriux S.A. (France), and Chembio Diagnostics (US).

Research Coverage
This report studies the point of care diagnostics market based on product type, platform, mode of purchase, end user and region. It also covers the factors affecting market growth, analyzes the various opportunities and challenges in the market, and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micromarkets with respect to their individual growth trends and forecasts the revenue of the market segments with respect to five main regions (and the respective countries in these regions).

Reasons to Buy the Report
The report will enable established firms as well as entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them to garner a larger market share. Firms purchasing the report could use one or a combination of the below-mentioned strategies for strengthening their market presence.

This report provides insights on the following pointers:
 Market Penetration: Comprehensive information on the product portfolios offered by the top players in the point of care diagnostics market
 Product Development/Innovation: Detailed insights on the upcoming trends, R&D activities, and product launches in the point of care diagnostics market
 Market Development: Comprehensive information on lucrative emerging regions
 Market Diversification: Exhaustive information about new products, growing geographies, and recent developments in the point of care diagnostics market
 Competitive Assessment: In-depth assessment of market segments, growth strategies, revenue analysis, and products of the leading market players.

【レポートの目次】

1 INTRODUCTION 39
1.1 OBJECTIVES OF THE STUDY 39
1.2 MARKET DEFINITION 39
1.2.1 INCLUSIONS & EXCLUSIONS OF THE STUDY 40
1.3 MARKET SCOPE 41
1.3.1 YEARS CONSIDERED FOR THE STUDY 42
1.4 CURRENCY USED FOR THE STUDY 42
TABLE 1 STANDARD CURRENCY CONVERSION RATES 42
1.5 LIMITATIONS 43
1.6 KEY MARKET STAKEHOLDERS 43
1.7 SUMMARY OF CHANGES 43
2 RESEARCH METHODOLOGY 45
2.1 RESEARCH DATA 45
FIGURE 1 RESEARCH DESIGN 45
2.1.1 SECONDARY DATA 46
2.1.1.1 Indicative list of secondary sources 47
2.1.2 PRIMARY DATA 48
2.1.2.1 Key industry insights 49
FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE,
DESIGNATION, AND REGION 49
FIGURE 3 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING 50
2.2 MARKET ESTIMATION METHODOLOGY 50
2.2.1 REVENUE MAPPING-BASED MARKET ESTIMATION 51
2.2.2 END-USER-BASED MARKET ESTIMATION 52
FIGURE 4 MARKET SIZE ESTIMATION METHODOLOGY:
POINT-OF-CARE DIAGNOSTICS MARKET 52
FIGURE 5 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS 53
2.2.3 PRIMARY RESEARCH VALIDATION 53
2.3 COVID-19 HEALTH ASSESSMENT 54
2.4 COVID-19 ECONOMIC ASSESSMENT 54
2.5 ASSESSMENT OF THE IMPACT OF COVID-19 ON THE ECONOMIC SCENARIO 55
FIGURE 6 CRITERIA IMPACTING THE GLOBAL ECONOMY 55
FIGURE 7 RECOVERY SCENARIO OF THE GLOBAL ECONOMY 56
2.6 DATA TRIANGULATION 57
FIGURE 8 DATA TRIANGULATION METHODOLOGY 57
2.7 RESEARCH ASSUMPTIONS & LIMITATIONS 58
2.7.1 ASSUMPTIONS FOR THE STUDY 58
2.8 RESEARCH LIMITATIONS 58
3 EXECUTIVE SUMMARY 59
FIGURE 9 POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT,
2021 VS. 2027 (USD MILLION) 59
FIGURE 10 POINT-OF-CARE DIAGNOSTICS MARKET, BY PLATFORM,
2021 VS. 2027 (USD MILLION) 60
FIGURE 11 POINT-OF-CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE,
2021 VS. 2027 (USD MILLION) 61
FIGURE 12 POINT-OF-CARE DIAGNOSTICS MARKET, BY END USER,
2021 VS. 2027 (USD MILLION) 61
FIGURE 13 GEOGRAPHICAL SNAPSHOT OF THE POINT-OF-CARE DIAGNOSTICS MARKET 62
4 PREMIUM INSIGHTS 63
4.1 POINT-OF-CARE DIAGNOSTICS MARKET OVERVIEW 63
FIGURE 14 RISING PREVALENCE OF TARGET DISEASES TO DRIVE MARKET GROWTH 63
4.2 IMPACT OF COVID-19 ON THE GLOBAL POINT-OF-CARE DIAGNOSTICS
MARKET (USD MILLION) 64
FIGURE 15 MARKET TO WITNESS A RISE DURING 2020–2021 OWING TO THE PANDEMIC 64
4.3 POINT-OF-CARE DIAGNOSTICS MARKET SHARE, BY MODE OF PURCHASE (2021) 64
FIGURE 16 OTC TESTING PRODUCTS DOMINATED THE POINT-OF-CARE DIAGNOSTICS MARKET IN 2021 64
4.4 ASIA PACIFIC: POINT-OF-CARE DIAGNOSTICS MARKET, BY END USER
AND COUNTRY (2021) 65
FIGURE 17 HOME CARE & SELF-TESTING IS THE LARGEST END-USER SEGMENT OF THE APAC POC DIAGNOSTICS MARKET 65
4.5 POINT-OF-CARE DIAGNOSTICS MARKET, BY REGION 66
FIGURE 18 LATIN AMERICA TO REGISTER THE HIGHEST GROWTH DURING THE FORECAST PERIOD (2022–2027) 66
5 MARKET OVERVIEW 67
5.1 INTRODUCTION 67
5.2 MARKET DYNAMICS 67
FIGURE 19 POINT-OF-CARE DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 67
5.2.1 DRIVERS 68
5.2.1.1 High prevalence of infectious diseases 68
5.2.1.2 Increasing incidence of target conditions 68
5.2.1.3 Supportive government policies 69
5.2.1.4 Dearth of skilled laboratory technicians 69
5.2.1.5 Rising number of CLIA-waived POC tests 70
TABLE 2 RECENT WAIVERS FOR MARKET PRODUCTS 70
5.2.2 RESTRAINTS 70
5.2.2.1 Pricing pressure owing to reimbursement cuts and
budget constraints 70
5.2.2.2 Stringent regulatory policies 71

5.2.3 OPPORTUNITIES 71
5.2.3.1 Emerging markets 71
5.2.3.2 Healthcare decentralization 72
5.2.3.3 Increasing provider awareness about novel technologies 72
5.2.3.4 POC tests with multiplexing capabilities 73
5.2.3.5 Growing investments and funding for product development 73
5.2.4 CHALLENGES 74
5.2.4.1 Lack of alignment with definitive central lab methods 74
5.2.4.2 Inadequate adoption of POC devices in professional settings 74
5.2.4.3 Reluctance to change existing diagnostic practices 75
5.2.4.4 Premium pricing of novel platforms 75
5.3 TECHNOLOGY ANALYSIS: EMERGING POINT-OF-CARE APPLICATIONS 75
5.3.1 SEPSIS BIOMARKERS 75
5.3.2 STROKE/CARDIAC MARKERS 76
5.3.3 THYROID TESTING 77
5.3.4 DNA TESTING 77
5.3.5 ENDOCRINE TESTING 77
5.3.6 RESPIRATORY DIAGNOSTICS 77
5.4 REGULATORY LANDSCAPE 78
5.5 INDUSTRY TRENDS RELATED TO COVID-19 79
5.6 VALUE CHAIN ANALYSIS 79
FIGURE 20 VALUE CHAIN ANALYSIS—MAXIMUM VALUE IS ADDED DURING THE REGULATION AND DISTRIBUTION STAGES 79
5.7 SUPPLY CHAIN ANALYSIS 80
5.7.1 PROMINENT COMPANIES 80
5.7.2 SMALL & MEDIUM-SIZED ENTERPRISES 80
5.7.3 END USERS 81
FIGURE 21 SUPPLY CHAIN ANALYSIS 81
5.8 PRICING TREND ANALYSIS 81
TABLE 3 AVERAGE PRICE OF GLUCOSE MONITORING AND CARDIOMETABOLIC MONITORING PRODUCTS, BY COUNTRY, 2021 (USD) 81
TABLE 4 AVERAGE PRICE OF INFECTIOUS DISEASE TESTING PRODUCTS,
BY COUNTRY, 2021 (USD) 82
TABLE 5 AVERAGE PRICE OF OTHER POINT-OF-CARE TESTING PRODUCTS,
BY COUNTRY, 2021 (USD) 82
5.9 PORTER’S FIVE FORCES 83
5.9.1 OVERVIEW 83
TABLE 6 POINT-OF-CARE DIAGNOSTICS MARKET: PORTER’S FIVE FORCES ANALYSIS 83
5.9.2 BARGAINING POWER OF BUYERS 83
5.9.3 BARGAINING POWER OF SUPPLIERS 83
5.9.4 THREAT OF NEW ENTRANTS 83
5.9.5 THREAT OF SUBSTITUTES 84
5.9.6 INTENSITY OF COMPETITIVE RIVALRY 84
5.10 PATENT ANALYSIS 84
FIGURE 22 PATENT APPLICANTS FOR POINT-OF-CARE TESTING 84
FIGURE 23 PATENT APPLICANTS FOR POINT-OF-CARE DIAGNOSTICS 84
FIGURE 24 ECOSYSTEM COVERAGE: PARENT MARKET (IN VITRO DIAGNOSTICS) 85
6 POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT 86
6.1 INTRODUCTION 87
TABLE 7 POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT,
2020–2027 (USD MILLION) 87
6.2 GLUCOSE MONITORING PRODUCTS 88
TABLE 8 POINT-OF-CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 88
TABLE 9 POINT-OF-CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY PLATFORM, 2020–2027 (USD MILLION) 89
TABLE 10 POINT-OF-CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY MODE OF PURCHASE, 2020–2027 (USD MILLION) 89
TABLE 11 POINT-OF-CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY END USER, 2020–2027 (USD MILLION) 90
TABLE 12 POINT-OF-CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY REGION, 2020–2027 (USD MILLION) 90
6.2.1 STRIPS 91
6.2.1.1 Strips make blood glucose testing easy and hassle-free 91
TABLE 13 GLUCOSE MONITORING STRIPS MARKET, BY REGION,
2020–2027 (USD MILLION) 91
6.2.2 METERS 91
6.2.2.1 Blood glucose meters are extremely helpful in the monitoring of blood glucose levels and adjusting therapeutic regimens 91
TABLE 14 GLUCOSE MONITORING METERS MARKET, BY REGION,
2020–2027 (USD MILLION) 92
6.2.3 LANCETS & LANCING DEVICES 92
6.2.3.1 Lancets & lancing devices segment to register lower growth in the glucose monitoring products market 92
TABLE 15 GLUCOSE MONITORING LANCETS & LANCING DEVICES MARKET, BY REGION, 2020–2027 (USD MILLION) 92
6.3 COVID-19 TESTING PRODUCTS 93
6.3.1 ONGOING PANDEMIC HAS INCREASED THE DEMAND FOR POC DIAGNOSTIC PRODUCTS 93
TABLE 16 POINT-OF-CARE DIAGNOSTICS MARKET FOR COVID-19 TESTING PRODUCTS, BY PLATFORM, 2020–2027 (USD MILLION) 94
TABLE 17 POINT-OF-CARE DIAGNOSTICS MARKET FOR COVID-19 TESTING PRODUCTS, BY MODE OF PURCHASE, 2020–2027 (USD MILLION) 94
TABLE 18 POINT-OF-CARE DIAGNOSTICS MARKET FOR COVID-19 TESTING PRODUCTS, BY END USER, 2020–2027 (USD MILLION) 95
TABLE 19 POINT-OF-CARE DIAGNOSTICS MARKET FOR COVID-19 TESTING PRODUCTS, BY REGION, 2020–2027 (USD MILLION) 95


6.4 CARDIOMETABOLIC MONITORING PRODUCTS 96
TABLE 20 POINT-OF-CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 96
TABLE 21 POINT-OF-CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY PLATFORM, 2020–2027 (USD MILLION) 96
TABLE 22 POINT-OF-CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY MODE OF PURCHASE,
2020–2027 (USD MILLION) 97
TABLE 23 POINT-OF-CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY END USER, 2020–2027 (USD MILLION) 97
TABLE 24 POINT-OF-CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY REGION, 2020–2027 (USD MILLION) 98
6.4.1 CARDIAC MARKER TESTING PRODUCTS 98
6.4.1.1 Rising government initiatives for CVD research will contribute to market growth 98
TABLE 25 POINT-OF-CARE DIAGNOSTICS MARKET FOR CARDIAC MARKER TESTING PRODUCTS, BY MODE OF PURCHASE, 2020–2027 (USD MILLION) 99
TABLE 26 POINT-OF-CARE DIAGNOSTICS MARKET FOR CARDIAC MARKER TESTING PRODUCTS, BY END USER, 2020–2027 (USD MILLION) 99
TABLE 27 POINT-OF-CARE DIAGNOSTICS MARKET FOR CARDIAC MARKER TESTING PRODUCTS, BY REGION, 2020–2027 (USD MILLION) 100
6.4.2 BLOOD GAS/ELECTROLYTE TESTING PRODUCTS 100
6.4.2.1 Technological advancements in blood gas/electrolyte products will drive the growth of this market segment 100
TABLE 28 POINT-OF-CARE DIAGNOSTICS MARKET FOR BLOOD GAS/ELECTROLYTE TESTING PRODUCTS, BY MODE OF PURCHASE, 2020–2027 (USD MILLION) 101
TABLE 29 POINT-OF-CARE DIAGNOSTICS MARKET FOR BLOOD GAS/ELECTROLYTE TESTING PRODUCTS, BY END USER, 2020–2027 (USD MILLION) 101
TABLE 30 POINT-OF-CARE DIAGNOSTICS MARKET FOR BLOOD GAS/ELECTROLYTE TESTING PRODUCTS, BY REGION, 2020–2027 (USD MILLION) 102
6.4.3 HBA1C TESTING PRODUCTS 102
6.4.3.1 Government initiatives are promoting the regular use of
HbA1c testing 102
TABLE 31 POINT-OF-CARE DIAGNOSTICS MARKET FOR HBA1C TESTING PRODUCTS,
BY MODE OF PURCHASE, 2020–2027 (USD MILLION) 103
TABLE 32 POINT-OF-CARE DIAGNOSTICS MARKET FOR HBA1C TESTING PRODUCTS,
BY END USER, 2020–2027 (USD MILLION) 103
TABLE 33 POINT-OF-CARE DIAGNOSTICS MARKET FOR HBA1C TESTING PRODUCTS,
BY REGION, 2020–2027 (USD MILLION) 104
6.5 INFECTIOUS DISEASE TESTING PRODUCTS 104
TABLE 34 POINT-OF-CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 105
TABLE 35 POINT-OF-CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY PLATFORM, 2020–2027 (USD MILLION) 105
TABLE 36 POINT-OF-CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY MODE OF PURCHASE, 2020–2027 (USD MILLION) 106
TABLE 37 POINT-OF-CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY END USER, 2020–2027 (USD MILLION) 106
TABLE 38 POINT-OF-CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY REGION, 2020–2027 (USD MILLION) 107
6.5.1 HIV TESTING PRODUCTS 107
6.5.1.1 Rising prevalence of HIV to drive market growth 107
TABLE 39 POINT-OF-CARE DIAGNOSTICS MARKET FOR HIV TESTING PRODUCTS,
BY MODE OF PURCHASE, 2020–2027 (USD MILLION) 108
TABLE 40 POINT-OF-CARE DIAGNOSTICS MARKET FOR HIV TESTING PRODUCTS,
BY END USER, 2020–2027 (USD MILLION) 108
TABLE 41 POINT-OF-CARE DIAGNOSTICS MARKET FOR HIV TESTING PRODUCTS,
BY REGION, 2020–2027 (USD MILLION) 109
6.5.2 RESPIRATORY INFECTION TESTING PRODUCTS 109
6.5.2.1 POCT products for the diagnosis of respiratory infections offer lower sensitivity as compared to other tests 109
TABLE 42 POINT-OF-CARE DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY MODE OF PURCHASE, 2020–2027 (USD MILLION) 110
TABLE 43 POINT-OF-CARE DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY END USER, 2020–2027 (USD MILLION) 110
TABLE 44 POINT-OF-CARE DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY REGION, 2020–2027 (USD MILLION) 111
6.5.3 HEPATITIS C TESTING PRODUCTS 111
6.5.3.1 Central and East Asia are among the highly affected regions
with hepatitis C 111
TABLE 45 POINT-OF-CARE DIAGNOSTICS MARKET FOR HEPATITIS C TESTING PRODUCTS, BY MODE OF PURCHASE, 2020–2027 (USD MILLION) 112
TABLE 46 POINT-OF-CARE DIAGNOSTICS MARKET FOR HEPATITIS C TESTING PRODUCTS, BY END USER, 2020–2027 (USD MILLION) 112
TABLE 47 POINT-OF-CARE DIAGNOSTICS MARKET FOR HEPATITIS C TESTING PRODUCTS, BY REGION, 2020–2027 (USD MILLION) 113
6.5.4 HEALTHCARE-ASSOCIATED INFECTION TESTING PRODUCTS 113
6.5.4.1 Rising prevalence of HAIs is the key factor driving market growth 113
TABLE 48 POINT-OF-CARE DIAGNOSTICS MARKET FOR HEALTHCARE-ASSOCIATED INFECTION TESTING PRODUCTS, BY MODE OF PURCHASE,
2020–2027 (USD MILLION) 113
TABLE 49 POINT-OF-CARE DIAGNOSTICS MARKET FOR HEALTHCARE-ASSOCIATED INFECTION TESTING PRODUCTS, BY END USER, 2020–2027 (USD MILLION) 114
TABLE 50 POINT-OF-CARE DIAGNOSTICS MARKET FOR HEALTHCARE-ASSOCIATED INFECTION TESTING PRODUCTS, BY REGION, 2020–2027 (USD MILLION) 114
6.5.5 INFLUENZA TESTING PRODUCTS 115
6.5.5.1 Rising influenza prevalence has driven the demand for influenza testing products 115
TABLE 51 POINT-OF-CARE DIAGNOSTICS MARKET FOR INFLUENZA TESTING PRODUCTS, BY MODE OF PURCHASE, 2020–2027 (USD MILLION) 115
TABLE 52 POINT-OF-CARE DIAGNOSTICS MARKET FOR INFLUENZA TESTING PRODUCTS, BY END USER, 2020–2027 (USD MILLION) 116
TABLE 53 POINT-OF-CARE DIAGNOSTICS MARKET FOR INFLUENZA TESTING PRODUCTS, BY REGION, 2020–2027 (USD MILLION) 116

6.5.6 TROPICAL DISEASE TESTING PRODUCTS 117
6.5.6.1 Increasing government funding for the use of POC in tropical disease testing will support market growth 117
TABLE 54 POINT-OF-CARE DIAGNOSTICS MARKET FOR TROPICAL DISEASE TESTING PRODUCTS, BY MODE OF PURCHASE, 2020–2027 (USD MILLION) 117
TABLE 55 POINT-OF-CARE DIAGNOSTICS MARKET FOR TROPICAL DISEASE TESTING PRODUCTS, BY END USER, 2020–2027 (USD MILLION) 118
TABLE 56 POINT-OF-CARE DIAGNOSTICS MARKET FOR TROPICAL DISEASE TESTING PRODUCTS, BY REGION, 2020–2027 (USD MILLION) 118
6.5.7 SEXUALLY TRANSMITTED DISEASE TESTING PRODUCTS 119
6.5.7.1 Privacy and confidentiality issues are the key factors leading to the adoption of POC STD testing products 119
TABLE 57 POINT-OF-CARE DIAGNOSTICS MARKET FOR STD TESTING PRODUCTS,
BY MODE OF PURCHASE, 2020–2027 (USD MILLION) 119
TABLE 58 POINT-OF-CARE DIAGNOSTICS MARKET FOR STD TESTING PRODUCTS,
BY END USER, 2020–2027 (USD MILLION) 120
TABLE 59 POINT-OF-CARE DIAGNOSTICS MARKET FOR STD TESTING PRODUCTS,
BY REGION, 2020–2027 (USD MILLION) 120
6.5.8 OTHER INFECTIOUS DISEASE TESTING PRODUCTS 121
TABLE 60 POINT-OF-CARE DIAGNOSTICS MARKET FOR OTHER INFECTIOUS DISEASE TESTING PRODUCTS, BY MODE OF PURCHASE, 2020–2027 (USD MILLION) 121
TABLE 61 POINT-OF-CARE DIAGNOSTICS MARKET FOR OTHER INFECTIOUS DISEASE TESTING PRODUCTS, BY END USER, 2020–2027 (USD MILLION) 122
TABLE 62 POINT-OF-CARE DIAGNOSTICS MARKET FOR OTHER INFECTIOUS DISEASE TESTING PRODUCTS, BY REGION, 2020–2027 (USD MILLION) 122
6.6 COAGULATION MONITORING PRODUCTS 123
TABLE 63 POINT-OF-CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 123
TABLE 64 POINT-OF-CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY PLATFORM, 2020–2027 (USD MILLION) 124
TABLE 65 POINT-OF-CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY MODE OF PURCHASE, 2020–2027 (USD MILLION) 124
TABLE 66 POINT-OF-CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY END USER, 2020–2027 (USD MILLION) 125
TABLE 67 POINT-OF-CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY REGION, 2020–2027 (USD MILLION) 125
6.6.1 PT/INR TESTING PRODUCTS 126
6.6.1.1 PT/INR is one of the most commonly used coagulation
monitoring methods 126
TABLE 68 POINT-OF-CARE DIAGNOSTICS MARKET FOR PT/INR TESTING PRODUCTS,
BY MODE OF PURCHASE, 2020–2027 (USD MILLION) 126
TABLE 69 POINT-OF-CARE DIAGNOSTICS MARKET FOR PT/INR TESTING PRODUCTS,
BY END USER, 2020–2027 (USD MILLION) 127
TABLE 70 POINT-OF-CARE DIAGNOSTICS MARKET FOR PT/INR TESTING PRODUCTS,
BY REGION, 2020–2027 (USD MILLION) 127
6.6.2 ACT/APTT TESTING PRODUCTS 128
6.6.2.1 Rising number of patients undergoing angioplasty and dialysis globally to support market growth 128
TABLE 71 POINT-OF-CARE DIAGNOSTICS MARKET FOR ACT/APTT TESTING PRODUCTS, BY MODE OF PURCHASE, 2020–2027 (USD MILLION) 128
TABLE 72 POINT-OF-CARE DIAGNOSTICS MARKET FOR ACT/APTT TESTING PRODUCTS, BY END USER, 2020–2027 (USD MILLION) 129
TABLE 73 POINT-OF-CARE DIAGNOSTICS MARKET FOR ACT/APTT TESTING PRODUCTS, BY REGION, 2020–2027 (USD MILLION) 129
6.7 PREGNANCY & FERTILITY TESTING PRODUCTS 130
TABLE 74 POINT-OF-CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 130
TABLE 75 POINT-OF-CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY PLATFORM, 2020–2027 (USD MILLION) 130
TABLE 76 POINT-OF-CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY MODE OF PURCHASE, 2020–2027 (USD MILLION) 131
TABLE 77 POINT-OF-CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY END USER, 2020–2027 (USD MILLION) 131
TABLE 78 POINT-OF-CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY REGION, 2020–2027 (USD MILLION) 132
6.7.1 PREGNANCY TESTING PRODUCTS 132
6.7.1.1 Rising inclination toward home testing to support market growth 132
TABLE 79 POINT-OF-CARE DIAGNOSTICS MARKET FOR PREGNANCY TESTING PRODUCTS, BY MODE OF PURCHASE, 2020–2027 (USD MILLION) 132
TABLE 80 POINT-OF-CARE DIAGNOSTICS MARKET FOR PREGNANCY TESTING PRODUCTS, BY END USER, 2020–2027 (USD MILLION) 133
TABLE 81 POINT-OF-CARE DIAGNOSTICS MARKET FOR PREGNANCY TESTING PRODUCTS, BY REGION, 2020–2027 (USD MILLION) 133
6.7.2 FERTILITY TESTING PRODUCTS 134
6.7.2.1 Increasing awareness of fertility testing to drive market growth 134
TABLE 82 POINT-OF-CARE DIAGNOSTICS MARKET FOR FERTILITY TESTING PRODUCTS, BY MODE OF PURCHASE, 2020–2027 (USD MILLION) 134
TABLE 83 POINT-OF-CARE DIAGNOSTICS MARKET FOR FERTILITY TESTING PRODUCTS, BY END USER, 2020–2027 (USD MILLION) 135
TABLE 84 POINT-OF-CARE DIAGNOSTICS MARKET FOR FERTILITY TESTING PRODUCTS, BY REGION, 2020–2027 (USD MILLION) 135
6.8 TUMOR/CANCER MARKER TESTING PRODUCTS 136
6.8.1 INCREASING INVESTMENTS FOR RESEARCH RELATED TO POC CANCER TESTING ARE DRIVING MARKET GROWTH 136
TABLE 85 POINT-OF-CARE DIAGNOSTICS MARKET FOR TUMOR/CANCER MARKER TESTING PRODUCTS, BY PLATFORM, 2020–2027 (USD MILLION) 136
TABLE 86 POINT-OF-CARE DIAGNOSTICS MARKET FOR TUMOR/CANCER MARKER TESTING PRODUCTS, BY MODE OF PURCHASE, 2020–2027 (USD MILLION) 137
TABLE 87 POINT-OF-CARE DIAGNOSTICS MARKET FOR TUMOR/CANCER MARKER TESTING PRODUCTS, BY END USER, 2020–2027 (USD MILLION) 137
TABLE 88 POINT-OF-CARE DIAGNOSTICS MARKET FOR HEMATOLOGY TESTING PRODUCTS, BY MODE OF PURCHASE, 2020–2027 (USD MILLION) 138
TABLE 89 POINT-OF-CARE DIAGNOSTICS MARKET FOR HEMATOLOGY TESTING PRODUCTS, BY END USER, 2020–2027 (USD MILLION) 138
TABLE 90 POINT-OF-CARE DIAGNOSTICS MARKET FOR HEMATOLOGY TESTING PRODUCTS, BY REGION, 2020–2027 (USD MILLION) 139
6.9 DRUGS-OF-ABUSE TESTING PRODUCTS 139
6.9.1 RISING CONSUMPTION OF ILLICIT DRUGS HAS BOOSTED
THE DEMAND FOR TESTING 139
TABLE 91 POINT-OF-CARE DIAGNOSTICS MARKET FOR DRUGS-OF-ABUSE TESTING PRODUCTS, BY PLATFORM, 2020–2027 (USD MILLION) 140
TABLE 92 POINT-OF-CARE DIAGNOSTICS MARKET FOR DRUGS-OF-ABUSE TESTING PRODUCTS, BY MODE OF PURCHASE, 2020–2027 (USD MILLION) 140
TABLE 93 POINT-OF-CARE DIAGNOSTICS MARKET FOR DRUGS-OF-ABUSE TESTING PRODUCTS, BY END USER, 2020–2027 (USD MILLION) 141
TABLE 94 POINT-OF-CARE DIAGNOSTICS MARKET FOR DRUGS-OF-ABUSE TESTING PRODUCTS, BY REGION, 2020–2027 (USD MILLION) 141
6.10 FECAL OCCULT TESTING PRODUCTS 142
6.10.1 LACK OF PROPER TRAINING IN THE USE OF FECAL OCCULT TESTING TO HAMPER MARKET ADOPTION 142
TABLE 95 POINT-OF-CARE DIAGNOSTICS MARKET FOR FECAL OCCULT TESTING PRODUCTS, BY PLATFORM, 2020–2027 (USD MILLION) 142
TABLE 96 POINT-OF-CARE DIAGNOSTICS MARKET FOR FECAL OCCULT TESTING PRODUCTS, BY MODE OF PURCHASE, 2020–2027 (USD MILLION) 143
TABLE 97 POINT-OF-CARE DIAGNOSTICS MARKET FOR FECAL OCCULT TESTING PRODUCTS, BY END USER, 2020–2027 (USD MILLION) 143
TABLE 98 POINT-OF-CARE DIAGNOSTICS MARKET FOR FECAL OCCULT TESTING PRODUCTS, BY REGION, 2020–2027 (USD MILLION) 144
6.11 OTHER PRODUCTS 144
TABLE 99 POINT-OF-CARE DIAGNOSTICS MARKET FOR OTHER POC PRODUCTS,
BY PLATFORM, 2020–2027 (USD MILLION) 144
TABLE 100 POINT-OF-CARE DIAGNOSTICS MARKET FOR OTHER PRODUCTS,
BY MODE OF PURCHASE, 2020–2027 (USD MILLION) 145
TABLE 101 POINT-OF-CARE DIAGNOSTICS MARKET FOR OTHER POC PRODUCTS,
BY END USER, 2020–2027 (USD MILLION) 145
TABLE 102 POINT-OF-CARE DIAGNOSTICS MARKET FOR OTHER POC PRODUCTS,
BY REGION, 2020–2027 (USD MILLION) 146
7 POINT-OF-CARE DIAGNOSTICS MARKET, BY PLATFORM 147
7.1 INTRODUCTION 148
TABLE 103 POINT-OF-CARE DIAGNOSTICS MARKET, BY PLATFORM,
2020–2027 (USD MILLION) 148
7.2 LATERAL FLOW ASSAYS 148
7.2.1 INCREASING ADOPTION OF LFA TESTING PRODUCTS IN HOME CARE SETTINGS TO DRIVE MARKET GROWTH 148
TABLE 104 POINT-OF-CARE DIAGNOSTICS MARKET FOR LATERAL FLOW ASSAYS,
BY REGION, 2020–2027 (USD MILLION) 149
7.3 IMMUNOASSAYS 149
7.3.1 RISING INCIDENCE OF CANCER AND GROWING AWARENESS ABOUT IMMUNOASSAY PLATFORMS TO SUPPORT MARKET GROWTH 149
TABLE 105 POINT-OF-CARE DIAGNOSTICS MARKET FOR IMMUNOASSAYS, BY REGION, 2020–2027 (USD MILLION) 150

7.4 MICROFLUIDICS 150
7.4.1 MICROFLUIDICS IS AN EMERGING PLATFORM IN THE POC
DIAGNOSTICS MARKET 150
TABLE 106 POINT-OF-CARE DIAGNOSTICS MARKET FOR MICROFLUIDICS, BY REGION, 2020–2027 (USD MILLION) 151
7.5 DIPSTICKS 151
7.5.1 DIPSTICKS HELP IN THE ROUTINE ANALYSIS OF SEVERAL
MEDICAL CONDITIONS 151
TABLE 107 POINT-OF-CARE DIAGNOSTICS MARKET FOR DIPSTICKS, BY REGION,
2020–2027 (USD MILLION) 152
7.6 MOLECULAR DIAGNOSTICS 152
7.6.1 INCREASING INITIATIVES BY MARKET PLAYERS FOR DEVELOPING POC MOLECULAR DIAGNOSTIC PRODUCTS TO DRIVE MARKET GROWTH 152
TABLE 108 POINT-OF-CARE DIAGNOSTICS MARKET FOR MOLECULAR DIAGNOSTICS,
BY REGION, 2020–2027 (USD MILLION) 153
8 POINT-OF-CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE 154
8.1 INTRODUCTION 155
TABLE 109 POINT-OF-CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE,
2020–2027 (USD MILLION) 155
8.2 OTC TESTING PRODUCTS 155
8.2.1 RISING FOCUS ON HOME CARE HAS BOOSTED THE DEMAND FOR
OTC TESTING PRODUCTS 155
TABLE 110 OTC POINT-OF-CARE TESTING PRODUCTS MARKET, BY REGION,
2020–2027 (USD MILLION) 156
8.3 PRESCRIPTION-BASED TESTING PRODUCTS 156
8.3.1 GROWING PREVALENCE OF LIFESTYLE DISEASES AND FAVORABLE REIMBURSEMENT HAVE DRIVEN MARKET GROWTH 156
TABLE 111 PRESCRIPTION-BASED POINT-OF-CARE TESTING PRODUCTS MARKET,
BY REGION, 2020–2027 (USD MILLION) 157
9 POINT-OF-CARE DIAGNOSTICS MARKET, BY END USER 158
9.1 INTRODUCTION 159
TABLE 112 POINT-OF-CARE DIAGNOSTICS MARKET, BY END USER,
2020–2027 (USD MILLION) 159
9.2 CLINICAL LABORATORIES 159
9.2.1 IMPROVEMENTS IN CLINICAL DIAGNOSTICS AND TESTING TECHNOLOGIES WILL BOOST MARKET GROWTH 159
TABLE 113 POINT-OF-CARE DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES,
BY REGION, 2020–2027 (USD MILLION) 160
9.3 AMBULATORY CARE FACILITIES & PHYSICIANS’ OFFICES 160
9.3.1 RAPID RESULT GENERATION AND AVAILABILITY OF IMMEDIATE PATIENT CARE ARE THE MAJOR FACTORS DRIVING MARKET GROWTH 160
TABLE 114 POINT-OF-CARE DIAGNOSTICS MARKET FOR AMBULATORY CARE FACILITIES & PHYSICIANS’ OFFICES, BY REGION, 2020–2027 (USD MILLION) 161

9.4 PHARMACIES, RETAIL CLINICS, & E-COMMERCE PLATFORMS 161
9.4.1 CONVENIENCE AND EASE OF EXPERT ACCESS TO DRIVE MARKET GROWTH 161
TABLE 115 POINT-OF-CARE DIAGNOSTICS MARKET FOR PHARMACIES, RETAIL CLINICS, & E-COMMERCE PLATFORMS, BY REGION, 2020–2027 (USD MILLION) 162
9.5 HOSPITALS, CRITICAL CARE CENTERS, & URGENT CARE CENTERS 162
9.5.1 HOSPITALS ARE AMONG THE LARGEST END USERS OF POC DIAGNOSTICS 162
TABLE 116 POINT-OF-CARE DIAGNOSTICS MARKET FOR HOSPITALS,
CRITICAL CARE CENTERS, & URGENT CARE CENTERS, BY REGION,
2020–2027 (USD MILLION) 163
9.6 HOME CARE & SELF-TESTING 163
9.6.1 INCREASING INCLINATION TOWARD HOME HEALTHCARE IS DRIVING THE GROWTH OF THIS END-USER SEGMENT 163
TABLE 117 POINT-OF-CARE DIAGNOSTICS MARKET FOR HOME CARE & SELF TESTING,
BY REGION, 2020–2027 (USD MILLION) 164
9.7 OTHER END USERS 164
TABLE 118 POINT-OF-CARE DIAGNOSTICS MARKET FOR OTHER END USERS, BY REGION, 2020–2027 (USD MILLION) 165
10 POINT-OF-CARE DIAGNOSTICS MARKET, BY REGION 166
10.1 INTRODUCTION 167
TABLE 119 POINT-OF-CARE DIAGNOSTICS MARKET, BY REGION,
2020–2027 (USD MILLION) 167
10.2 NORTH AMERICA 168
FIGURE 25 NORTH AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET SNAPSHOT 168
TABLE 120 NORTH AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 168
TABLE 121 NORTH AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 169
TABLE 122 NORTH AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 169
TABLE 123 NORTH AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE,
2020–2027 (USD MILLION) 170
TABLE 124 NORTH AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 170
TABLE 125 NORTH AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE,
2020–2027 (USD MILLION) 171
TABLE 126 NORTH AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 171
TABLE 127 NORTH AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET, BY PLATFORM, 2020–2027 (USD MILLION) 171
TABLE 128 NORTH AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET,
BY MODE OF PURCHASE, 2020–2027 (USD MILLION) 172
TABLE 129 NORTH AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET, BY END USER, 2020–2027 (USD MILLION) 172

10.2.1 US 173
10.2.1.1 The US dominates the North American POC diagnostics market 173
TABLE 130 US: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT,
2020–2027 (USD MILLION) 174
TABLE 131 US: POINT-OF-CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 175
TABLE 132 US: POINT-OF-CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 175
TABLE 133 US: POINT-OF-CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 176
TABLE 134 US: POINT-OF-CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 176
10.2.2 CANADA 176
10.2.2.1 Rising government initiatives to support the growth of the
POC diagnostics market in Canada 176
TABLE 135 CANADA: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT,
2020–2027 (USD MILLION) 178
TABLE 136 CANADA: POINT-OF-CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 178
TABLE 137 CANADA: POINT-OF-CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 179
TABLE 138 CANADA: POINT-OF-CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 179
TABLE 139 CANADA: POINT-OF-CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 180

10.3 EUROPE 180
TABLE 140 EUROPE: POINT-OF-CARE DIAGNOSTICS MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 180
TABLE 141 EUROPE: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT,
2020–2027 (USD MILLION) 181
TABLE 142 EUROPE: POINT-OF-CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 181
TABLE 143 EUROPE: POINT-OF-CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 182
TABLE 144 EUROPE: POINT-OF-CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 182
TABLE 145 EUROPE: POINT-OF-CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 183
TABLE 146 EUROPE: POINT-OF-CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 183
TABLE 147 EUROPE: POINT-OF-CARE DIAGNOSTICS MARKET, BY PLATFORM,
2020–2027 (USD MILLION) 183
TABLE 148 EUROPE: POINT-OF-CARE DIAGNOSTICS MARKET, BY MODE OF PURCHASE, 2020–2027 (USD MILLION) 184
TABLE 149 EUROPE: POINT-OF-CARE DIAGNOSTICS MARKET, BY END USER,
2020–2027 (USD MILLION) 184

10.3.1 GERMANY 185
10.3.1.1 Germany accounts for the largest share of the European market 185
TABLE 150 GERMANY: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT,
2020–2027 (USD MILLION) 186
TABLE 151 GERMANY: POINT-OF-CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 186
TABLE 152 GERMANY: POINT-OF-CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 187
TABLE 153 GERMANY: POINT-OF-CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 187
TABLE 154 GERMANY: POINT-OF-CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 188
10.3.2 FRANCE 188
10.3.2.1 Growing public-private collaborations for product development to drive market growth 188
TABLE 155 FRANCE: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT,
2020–2027 (USD MILLION) 189
TABLE 156 FRANCE: POINT-OF-CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 189
TABLE 157 FRANCE: POINT-OF-CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 190
TABLE 158 FRANCE: POINT-OF-CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 190
TABLE 159 FRANCE: POINT-OF-CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 191
10.3.3 UK 191
10.3.3.1 Growing awareness of the benefits offered by POC diagnostics to support market growth in the UK 191
TABLE 160 UK: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT,
2020–2027 (USD MILLION) 192
TABLE 161 UK: POINT-OF-CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 193
TABLE 162 UK: POINT-OF-CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 193
TABLE 163 UK: POINT-OF-CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 194
TABLE 164 UK: POINT-OF-CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 194
10.3.4 ITALY 194
10.3.4.1 Rising prevalence of chronic diseases in Italy to drive the demand for point-of-care diagnostics 194
TABLE 165 ITALY: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT,
2020–2027 (USD MILLION) 195
TABLE 166 ITALY: POINT-OF-CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 195
TABLE 167 ITALY: POINT-OF-CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 196
TABLE 168 ITALY: POINT-OF-CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 196
TABLE 169 ITALY: POINT-OF-CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 197
10.3.5 SPAIN 197
10.3.5.1 Increasing funding for research in Spain to boost the market growth 197
TABLE 170 SPAIN: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT,
2020–2027 (USD MILLION) 198
TABLE 171 SPAIN: POINT-OF-CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 198
TABLE 172 SPAIN: POINT-OF-CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 199
TABLE 173 SPAIN: POINT-OF-CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 199
TABLE 174 SPAIN: POINT-OF-CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 200
10.3.6 REST OF EUROPE 200
TABLE 175 REST OF EUROPE: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 201
TABLE 176 REST OF EUROPE: POINT-OF-CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE,
2020–2027 (USD MILLION) 201
TABLE 177 REST OF EUROPE: POINT-OF-CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 202
TABLE 178 REST OF EUROPE: POINT-OF-CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE,
2020–2027 (USD MILLION) 202
TABLE 179 REST OF EUROPE: POINT-OF-CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 203
10.4 ASIA PACIFIC 203
TABLE 180 ASIA PACIFIC: POINT-OF-CARE DIAGNOSTICS MARKET, BY COUNTRY,
2020–2027 (USD MILLION) 203
TABLE 181 ASIA PACIFIC: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT,
2020–2027 (USD MILLION) 204
TABLE 182 ASIA PACIFIC: POINT-OF-CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 204
TABLE 183 ASIA PACIFIC: POINT-OF-CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE,
2020–2027 (USD MILLION) 205
TABLE 184 ASIA PACIFIC: POINT-OF-CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 205
TABLE 185 ASIA PACIFIC: POINT-OF-CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 206
TABLE 186 ASIA PACIFIC: POINT-OF-CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 206
TABLE 187 ASIA PACIFIC: POINT-OF-CARE DIAGNOSTICS MARKET, BY PLATFORM, 2020–2027 (USD MILLION) 206
TABLE 188 ASIA PACIFIC: POINT-OF-CARE DIAGNOSTICS MARKET,
BY MODE OF PURCHASE, 2020–2027 (USD MILLION) 207
TABLE 189 ASIA PACIFIC: POINT-OF-CARE DIAGNOSTICS MARKET, BY END USER,
2020–2027 (USD MILLION) 207
10.4.1 JAPAN 208
10.4.1.1 Japan to dominate the APAC POC diagnostics market during the forecast period 208
TABLE 190 JAPAN: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT,
2020–2027 (USD MILLION) 209
TABLE 191 JAPAN: POINT-OF-CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 209
TABLE 192 JAPAN: POINT-OF-CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 210
TABLE 193 JAPAN: POINT-OF-CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 210
TABLE 194 JAPAN: POINT-OF-CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 211
10.4.2 CHINA 211
10.4.2.1 Rising investments by market players and the Chinese government to drive market growth 211
TABLE 195 CHINA: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT,
2020–2027 (USD MILLION) 212
TABLE 196 CHINA: POINT-OF-CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 213
TABLE 197 CHINA: POINT-OF-CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 213
TABLE 198 CHINA: POINT-OF-CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 214
TABLE 199 CHINA: POINT-OF-CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 214
10.4.3 INDIA 214
10.4.3.1 High burden of chronic diseases to support market growth 214
TABLE 200 INDIA: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT,
2020–2027 (USD MILLION) 216
TABLE 201 INDIA: POINT-OF-CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 216
TABLE 202 INDIA: POINT-OF-CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 217
TABLE 203 INDIA: POINT-OF-CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 217
10.4.4 AUSTRALIA 218
10.4.4.1 Government initiatives to support the adoption of
point-of-care testing 218
TABLE 204 AUSTRALIA: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT,
2020–2027 (USD MILLION) 218
TABLE 205 AUSTRALIA: POINT-OF-CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 219
TABLE 206 AUSTRALIA: POINT-OF-CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 219
TABLE 207 AUSTRALIA: POINT-OF-CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 220
TABLE 208 AUSTRALIA: POINT-OF-CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 220
10.4.5 SOUTH KOREA 220
10.4.5.1 Increased funding and product development to propel market growth 220
TABLE 209 SOUTH KOREA: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 221
TABLE 210 SOUTH KOREA: POINT-OF-CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE,
2020–2027 (USD MILLION) 221
TABLE 211 SOUTH KOREA: POINT-OF-CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 222
TABLE 212 SOUTH KOREA: POINT-OF-CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 222
TABLE 213 SOUTH KOREA: POINT-OF-CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 223
10.4.6 REST OF ASIA PACIFIC 223
TABLE 214 REST OF ASIA PACIFIC: POINT-OF-CARE DIAGNOSTICS MARKET,
BY PRODUCT, 2020–2027 (USD MILLION) 224
TABLE 215 REST OF ASIA PACIFIC: POINT-OF-CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE,
2020–2027 (USD MILLION) 224
TABLE 216 REST OF ASIA PACIFIC: POINT-OF-CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE,
2020–2027 (USD MILLION) 225
TABLE 217 REST OF ASIA PACIFIC: POINT-OF-CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE,
2020–2027 (USD MILLION) 225
TABLE 218 REST OF ASIA PACIFIC: POINT-OF-CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE,
2020–2027 (USD MILLION) 226
10.5 LATIN AMERICA 226
FIGURE 26 LATIN AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET SNAPSHOT 227
TABLE 219 LATIN AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET, BY COUNTRY, 2020–2027 (USD MILLION) 227
TABLE 220 LATIN AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT, 2020–2027 (USD MILLION) 228
TABLE 221 LATIN AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 228
TABLE 222 LATIN AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE,
2020–2027 (USD MILLION) 229
TABLE 223 LATIN AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 229
TABLE 224 LATIN AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 230
TABLE 225 LATIN AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 230
TABLE 226 LATIN AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET, BY PLATFORM, 2020–2027 (USD MILLION) 230
TABLE 227 LATIN AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET,
BY MODE OF PURCHASE, 2020–2027 (USD MILLION) 231
TABLE 228 LATIN AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET, BY END USER, 2020–2027 (USD MILLION) 231
10.5.1 BRAZIL 232
10.5.1.1 Rising prevalence of diabetes to support market growth in Brazil 232
TABLE 229 BRAZIL: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT,
2020–2027 (USD MILLION) 232
TABLE 230 BRAZIL: POINT-OF-CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 233
TABLE 231 BRAZIL: POINT-OF-CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 233
TABLE 232 BRAZIL: POINT-OF-CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 234
TABLE 233 BRAZIL: POINT-OF-CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 234
10.5.2 MEXICO 234
10.5.2.1 Rising prevalence of diabetes and cancer to support market growth in Mexico 234
TABLE 234 MEXICO: POINT-OF-CARE DIAGNOSTICS MARKET, BY PRODUCT,
2020–2027 (USD MILLION) 235
TABLE 235 MEXICO: POINT-OF-CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 235
TABLE 236 MEXICO: POINT-OF-CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 236
TABLE 237 MEXICO: POINT-OF-CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 236
TABLE 238 MEXICO: POINT-OF-CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 237
10.5.3 REST OF LATIN AMERICA 237
TABLE 239 REST OF LATIN AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET,
BY PRODUCT, 2020–2027 (USD MILLION) 238
TABLE 240 REST OF LATIN AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE,
2020–2027 (USD MILLION) 238
TABLE 241 REST OF LATIN AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE,
2020–2027 (USD MILLION) 239
TABLE 242 REST OF LATIN AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE,
2020–2027 (USD MILLION) 239
TABLE 243 REST OF LATIN AMERICA: POINT-OF-CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE,
2020–2027 (USD MILLION) 240
10.6 MIDDLE EAST & AFRICA 240
10.6.1 RISING PREVALENCE OF CANCER TO SUPPORT MARKET GROWTH IN THE MEA 240
TABLE 244 MIDDLE EAST & AFRICA: POINT-OF-CARE DIAGNOSTICS MARKET,
BY PRODUCT, 2020–2027 (USD MILLION) 241
TABLE 245 MIDDLE EAST & AFRICA: POINT-OF-CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2020–2027 (USD MILLION) 241
TABLE 246 MIDDLE EAST & AFRICA: POINT-OF-CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE,
2020–2027 (USD MILLION) 242
TABLE 247 MIDDLE EAST & AFRICA: POINT-OF-CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TYPE,
2020–2027 (USD MILLION) 242
TABLE 248 MIDDLE EAST & AFRICA: POINT-OF-CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY TYPE,
2020–2027 (USD MILLION) 243
TABLE 249 MIDDLE EAST & AFRICA: POINT-OF-CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY TYPE,
2020–2027 (USD MILLION) 243
TABLE 250 MIDDLE EAST & AFRICA: POINT-OF-CARE DIAGNOSTICS MARKET,
BY PLATFORM, 2020–2027 (USD MILLION) 243
TABLE 251 MIDDLE EAST & AFRICA: POINT-OF-CARE DIAGNOSTICS MARKET,
BY MODE OF PURCHASE, 2020–2027 (USD MILLION) 244
TABLE 252 MIDDLE EAST & AFRICA: POINT-OF-CARE DIAGNOSTICS MARKET,
BY END USER, 2020–2027 (USD MILLION) 244
11 COMPETITIVE LANDSCAPE 245
11.1 INTRODUCTION 245
FIGURE 27 KEY DEVELOPMENTS BY LEADING PLAYERS IN THE POINT-OF-CARE DIAGNOSTICS MARKET, JANUARY 2018–FEBRUARY 2022 246
11.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 246
11.3 REVENUE SHARE ANALYSIS 247
FIGURE 28 REVENUE SHARE ANALYSIS OF THE TOP PLAYERS IN THE
POINT-OF-CARE DIAGNOSTICS MARKET 247
11.4 MARKET SHARE ANALYSIS 248
FIGURE 29 TOTAL POINT-OF-CARE DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2021 248
FIGURE 30 TOTAL POINT-OF-CARE DIAGNOSTICS (WITHOUT COVID) MARKET SHARE,
BY KEY PLAYER, 2021 248
FIGURE 31 TOTAL POINT-OF-CARE DIAGNOSTICS (ONLY COVID) MARKET SHARE,
BY KEY PLAYER, 2021 249
TABLE 253 POINT-OF-CARE DIAGNOSTICS MARKET: DEGREE OF COMPETITION 249
11.5 COMPETITIVE LEADERSHIP MAPPING: COMPANY EVALUATION QUADRANT (2021) 250
11.5.1 STARS 250
11.5.2 EMERGING LEADERS 251
11.5.3 PERVASIVE PLAYERS 251
11.5.4 PARTICIPANTS 251
FIGURE 32 POINT-OF-CARE DIAGNOSTICS MARKET: COMPETITIVE LEADERSHIP MAPPING (2021) 251
11.6 COMPETITIVE LEADERSHIP MAPPING: START-UP/ SME EVALUATION QUADRANT (2021) 252
11.6.1 PROGRESSIVE COMPANIES 252
11.6.2 RESPONSIVE COMPANIES 252
11.6.3 DYNAMIC COMPANIES 252
11.6.4 STARTING BLOCKS 252
FIGURE 33 POINT OF CARE MARKET: COMPETITIVE LEADERSHIP MAPPING (SMES/START-UPS) (2021) 253
11.7 COMPETITIVE BENCHMARKING 254
TABLE 254 COMPANY FOOTPRINT ANALYSIS IN THE POINT-OF-CARE
DIAGNOSTICS MARKET 254
11.8 COMPETITIVE SCENARIO 255
11.8.1 PRODUCT LAUNCHES & APPROVALS 255
11.8.2 DEALS 262
12 COMPANY PROFILES 266
12.1 KEY PLAYERS 266
(Business Overview, Products Offered, Recent Developments, and MnM View)*
12.1.1 F. HOFFMANN-LA ROCHE LTD. 266
TABLE 255 F. HOFFMANN-LA ROCHE LTD.: BUSINESS OVERVIEW 266
FIGURE 34 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2021) 267
12.1.2 ABBOTT 273
TABLE 256 ABBOTT: BUSINESS OVERVIEW 273
FIGURE 35 ABBOTT: COMPANY SNAPSHOT (2021) 274
12.1.3 SIEMENS HEALTHINEERS AG 280
TABLE 257 SIEMENS HEALTHINEERS AG: BUSINESS OVERVIEW 280
FIGURE 36 SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT (2021) 281
12.1.4 QUIDEL CORPORATION 286
TABLE 258 QUIDEL CORPORATION: BUSINESS OVERVIEW 286
FIGURE 37 QUIDEL CORPORATION: COMPANY SNAPSHOT (2021) 287
12.1.5 DANAHER CORPORATION 292
TABLE 259 DANAHER CORPORATION: BUSINESS OVERVIEW 292
FIGURE 38 DANAHER CORPORATION: COMPANY SNAPSHOT (2020) 293
12.1.6 BECTON, DICKINSON AND COMPANY 296
TABLE 260 BECTON, DICKINSON AND COMPANY: BUSINESS OVERVIEW 296
FIGURE 39 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2021) 297
12.1.7 THERMO FISHER SCIENTIFIC 300
TABLE 261 THERMO FISHER SCIENTIFIC: BUSINESS OVERVIEW 300
FIGURE 40 THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT (2020) 301
12.1.8 BIOMÉRIEUX S.A. 306
TABLE 262 BIOMÉRIEUX S.A.: BUSINESS OVERVIEW 306
FIGURE 41 BIOMÉRIEUX S.A.: COMPANY SNAPSHOT (2020) 307
12.1.9 CHEMBIO DIAGNOSTICS, INC. 313
TABLE 263 CHEMBIO DIAGNOSTICS, INC.: BUSINESS OVERVIEW 313
FIGURE 42 CHEMBIO DIAGNOSTICS: COMPANY SNAPSHOT (2020) 314
12.1.10 EKF DIAGNOSTICS 317
TABLE 264 EKF DIAGNOSTICS: BUSINESS OVERVIEW 317
FIGURE 43 EKF DIAGNOSTICS: COMPANY SNAPSHOT (2020) 318
12.1.11 TRINITY BIOTECH PLC 320
TABLE 265 TRINITY BIOTECH PLC: BUSINESS OVERVIEW 320
FIGURE 44 TRINITY BIOTECH PLC: COMPANY SNAPSHOT (2020) 321
12.1.12 INSTRUMENTATION LABORATORY (A WERFEN COMPANY) 323
TABLE 266 INSTRUMENTATION LABORATORY: BUSINESS OVERVIEW 323
12.1.13 NOVA BIOMEDICAL 326
TABLE 267 NOVA BIOMEDICAL: BUSINESS OVERVIEW 326
12.1.14 PTS DIAGNOSTICS 329
TABLE 268 PTS DIAGNOSTICS: BUSINESS OVERVIEW 329
12.1.15 SEKISUI DIAGNOSTICS 331
TABLE 269 SEKISUI DIAGNOSTICS: BUSINESS OVERVIEW 331
12.1.16 HOLOGIC, INC. 333
TABLE 270 HOLOGIC, INC.: BUSINESS OVERVIEW 333
FIGURE 45 HOLOGIC, INC.: COMPANY SNAPSHOT (2021) 334
12.1.17 QIAGEN 338
TABLE 271 QIAGEN: BUSINESS OVERVIEW 338
FIGURE 46 QIAGEN: COMPANY SNAPSHOT (2021) 339
* Business Overview, Products Offered, Recent Developments, and MnM View might not be captured in case of unlisted companies.
12.2 OTHER PLAYERS 342
12.2.1 LIFESCAN IP HOLDINGS, LLC 342
12.2.2 ASCENSIA DIABETES CARE HOLDINGS AG 343
12.2.3 FLUXERGY 344
12.2.4 PRESCISION BIOSENSOR, INC. 345
12.2.5 ACON LABORATORIES, INC. 345
12.2.6 A. MENARINI DIAGNOSTICS S.R.L 347
12.2.7 ORASURE TECHNOLOGIES, INC. 348
12.2.8 MANKIND PHARMA 349
12.2.9 TERUMO CORPORATION 350
12.2.10 GRIFOLS, S.A. 351
12.2.11 DIASORIN S.P.A. 352
12.2.12 ACCUBIOTECH CO., LTD. 353
12.2.13 MERIDIAN BIOSCIENCE 354
12.2.14 BIOCARTIS 355
12.2.15 GENESTAT MOLECULAR DIAGNOSTICS, LLC. 356
12.2.16 ELLUME LIMITED 357
12.2.17 LUCIRA HEALTH, INC. 357
12.2.18 CUE HEALTH 358
12.2.19 BINX HEALTH, INC. 359
12.2.20 MOLBIO DIAGNOSTICS PVT. LTD. 360
12.2.21 VISBY MEDICAL, INC. 361
12.2.22 QUIKPATH PTE. LTD. 361
13 APPENDIX 362
13.1 DISCUSSION GUIDE 362
13.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 367
13.3 AVAILABLE CUSTOMIZATIONS 369
13.4 RELATED REPORTS 369
13.5 AUTHOR DETAILS 370

★調査レポート[ポイントオブケア(POC)&迅速診断の世界市場予測(~2027):製品別、プラットフォーム別、購入方法別、エンドユーザー別] ( Point of Care & Rapid Diagnostics Market by Product (Glucose, Infectious Disease(HIV, Hepatitis C), Pregnancy Test), Platform (Microfluidics, Dipsticks), Mode of Purchase (OTC, Prescription), End User (Pharmacy, Hospital, Home) - Global Forecast to 2027 / MD2702-22) 販売に関する免責事項
[ポイントオブケア(POC)&迅速診断の世界市場予測(~2027):製品別、プラットフォーム別、購入方法別、エンドユーザー別] ( Point of Care & Rapid Diagnostics Market by Product (Glucose, Infectious Disease(HIV, Hepatitis C), Pregnancy Test), Platform (Microfluidics, Dipsticks), Mode of Purchase (OTC, Prescription), End User (Pharmacy, Hospital, Home) - Global Forecast to 2027 / MD2702-22) についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆